The trial that is being conducted at City of Hope Comprehensive Cancer Center, will assess the activity of CRLX101 in HER-2 negative gastric cancer patients with progressed disease subsequent to the standard frontline therapy.
Post-dosing tumour biopsies will assist in determining if CRLX101 is localised to human gastric tumour tissue.
Cerulean chief medical officer Edward Garmey said, "We are fortunate to have another opportunity to collaborate with Drs. Yen and Davis to further elucidate the tumour-targeting mechanism of nanopharmaceuticals and to potentially address the significant unmet medical need in gastric cancer."
CRLX101 investigational agent will release camptothecin over a long time, extending the drug exposure at the site of action.
The anti-cancer agent is a nanopharmaceutical dual inhibitor of topoisomerase 1 and hypoxia-inducible factor-1 alpha.